A Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Conditions:   Carcinoma, Hepatocellular;   Biliary Tract Cancer;   Secondary Liver Cancer;   Liver Metastases Interventions:   Drug: RO7119929;   Drug: Tocilizumab Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials